High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine.

CONCLUSION: Prediabetes and metabolic abnormalities were highly prevalent among the clozapine- and olanzapine-treated patients with schizophrenia, putting these patients at great risk for later type 2 diabetes and cardiovascular disease. These results stress the importance of identifying and adequately treating prediabetes and metabolic abnormalities among clozapine- and olanzapine-treated patients with schizophrenia.
PMID: 30596361 [PubMed - as supplied by publisher]

Source: CNS Spectrums - December 31, 2018 Category: Neurology Authors: Larsen JR, Svensson CK, Vedtofte L, Jakobsen ML, Jespersen HS, Jakobsen MI, Koyuncu K, Schjerning O, Nielsen J, Ekstrøm CT, Holst JJ, Correll CU, Vilsbøll T, Fink-Jensen A Tags: CNS Spectr Source Type: research